Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
Condition(s):Metastatic Pancreatic CancerLast Updated:February 8, 2022Unknown status
Hide Studies Not Open or Pending
Condition(s):Metastatic Pancreatic CancerLast Updated:February 8, 2022Unknown status
Condition(s):Pancreatic NeoplasmLast Updated:February 26, 2024Active, not recruiting
Condition(s):Pancreatic Cancer; Colorectal Cancer; Rectal Cancer; Gastric Cancer; Esophageal Cancer; Gastrointestinal Stromal Tumor (GIST)Last Updated:October 2, 2019Completed
Condition(s):Pancreatic NeoplasmLast Updated:February 3, 2022Unknown status
Condition(s):Pancreatic CancerLast Updated:August 17, 2021Completed
Condition(s):Pancreatic CancerLast Updated:July 27, 2017Terminated
Condition(s):Pancreatic NeoplasmsLast Updated:September 16, 2019Terminated
Condition(s):Stage IA Pancreatic Adenocarcinoma; Stage IB Pancreatic Adenocarcinoma; Stage IIA Pancreatic Adenocarcinoma; Stage IIB Pancreatic AdenocarcinomaLast Updated:February 5, 2019Completed
Condition(s):Metastatic Pancreatic Adenocarcinoma; Metastatic Pancreatic CancerLast Updated:May 28, 2020Completed
Condition(s):Pancreatic CancerLast Updated:July 11, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.